ArticleNPJ precision oncology2025
Comprehensive single-cell transcriptome landscape of metastatic colorectal cancer identifies budding-potential cells and their interactions with cancer-associated fibroblasts.
Article in NPJ precision oncology, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 4 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
4 citing papers in PubMed.
- Preoperative [European radiology · 2026Article
- Multi-omics-driven precision medicine.iMeta · 2026Review
- A mitoxyperilysis-related signature stratifies prognosis and identifies an aggressive colorectal cancer ecosystem with immune remodeling.Frontiers in cell and developmental biology · 2026Article
- Investigate the heterogeneity of colorectal cancer patients at the single-cell level prior to and subsequent to immunotherapy.Frontiers in immunology · 2026Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
11 authors.
Funding
Abstract
Tumor budding is positively associated with colorectal cancer (CRC) metastasis. In this study, we integrated a single-cell transcriptomic dataset of 287 CRC samples to comprehensively illustrate the transcriptomic landscape of metastatic CRC and identified a unique subcluster of tumor epithelial cells associated with tumor budding. This subcluster exhibited high mesothelin (MSLN) expression and was located at the invasive front of CRC. MSLN was confirmed to promote CRC growth and metastasis by in vitro and in vivo models. Also, POSTN
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.